A Synthesis, Properties and Application as a Possible Drug Delivery Systems Dendrimers – A Review
DOI:
https://doi.org/10.22270/ajprd.v8i2.676Keywords:
Dendrimers, Properties, Classification, Types, And Application.Abstract
Dendrimer is derived from the Greek word “dendron” which is used for tree and from the Greek suffix “mer” (segment) which describes the synthetic, three-dimensional molecules having branching parts.“A dendrimer is generally described as a macromolecule, which is characterized by its dendritic and hyper branched 3D structure that offers a high degree of surface functionality and versatility.” Dendrimers possess three distinguishable architectural components i.e. an interior core, interior layer(generations) composed of repeating units radially attached to the interior core, and exterior (terminal functionality) attached to outermost interior generation (Fig. 1). The higher generation dendrimers, due to their globular structure, occupy a smaller hydrodynamic volume compared to the corresponding linear polymers. The dendritic structure is characterized by layer between each generation.Dendrimers are generally prepared using either a divergent method or a convergent one. There is a fundamental difference between these two construction concepts. Dendrimers shows the various properties such as structure, shape, aqueous solubility, non-polar solubility, &architecture. Dendrimer can be classification on the basis of their shape, structure, branching, solubility, chirality and attachment. Dendrimer can be differentiated on the basis of their shape, end functional groups and internal cavities.
Downloads
References
2. BhartiJP, Prajapati SK, Jaiswal MK and Yadav RD, Dendrimer Multifunctional Nano-Device: A Review. IJPSR, 2011; 2(8):1947-1960.
3. JainK, KesharwaniP, GuptaU, JainNK, Dendrimer toxicity: Let’s meet the challenge. International Journal of Pharmaceutics, 2010; 394: 122–142.
4. Baig T, Nayak J, Dwivedi V, Singh A, Srivastava and Tripathi PK, A Review about Dendrimers: Synthesis, Types, Characterization and Applications. IJAPBC, 2015; 4(1): 44-59.
5. Hodge, P. Polymer science branches out. Nature, 1993; 362:18–19.
6. HawkerCJ &Fréchet JMJ, Preparation of polymers with controlled molecular architecture. A new convergent approach to dendritic macromolecules, J. Am. Chem. Soc. 1990; 112:7638–7647.
7. Sonke, S and Tomalia DA, Dendrimers in biomedical applications reflections on the Field. Advanced Drug Delivery Reviews, 2005; 57: 2106 –2129.
8. Shinde GV, Bangale GS, Umalkar DK, Rathinaraj BS, Yadav CS, Yadav P, Dendrimers. Journal of Pharmaceutical and Biomedical Sciences, 2010; 03(03):1-8.
9. Tomalia DA, Naylor AM, Goddard WA, Starburst Dendrimers: Molecular- Level Control of Size, Shape, Suface Chemistry, Topology and Flexibility from Atoms to Macroscopic Matter. Angewandte International Edition England, 1990; 29(2):138-175.
10. Roseita E, Tomalia DA, Poly (amidoamine) (PAMAM) dendrimers: from. biomimicry to drug delivery and biomedical applications. Drug Delivery Today, 2001; 6(8):427-436.
11. Schiavon O, Pasut G, Moro S, PEG-Ara-C conjugates for controlled release. European Journal of Medicinal Chemistry, 2004; 39(2): 123-133.
12. Brana MF, Dominguez G, Saez B, Synthesis and anti-tumor activity of new dendritic polyamines(imide-DNA-intercalator) conjugates: potent Lck inhibitors. European Journal of Medicinal Chemistry, 2002; 37(7):541-551.
13. Hawaker C, Wooley KL, Frechet JMJ, Unimolecular micelles and globular amphiphiles: dendritic macromolecules as novel recyclable solubilization agents. Journal of Chemical Society. Perkin Transactions, 1993; 1(12):1287-1289.
14. Pushkar S, Philip A, Pathak K, Pathak D, Dendrimers: Nanotechnology Derived field, Polymers in Drug Delivery. Indian Journal of Pharmaceutical Education and Research, 2006; 40(3):153-158.
15. Yasukawa T, Ogura Y, Tabata Y, Kimura H, Wiedemann P, Honda Y, Drug delivery systems for vitreo retinal diseases. Progress in Retinal and Eye Research, 2004; 23(3):253–281.
16. Tripathi S, Das MK,Dendrimers and their Applications as Novel Drug Delivery Carriers. Journal of Applied Pharmaceutical Science, 2013; 3(09):142-149.
17. Duncan R, Malik N, Richardson S. and Ferruti P, Dendrimernanocomposites in medicine, Polym. Prep, 1998; 39: 180.
18. Jain NK,Advances in Controlled and Novel Drug Delivery, CBS Publishers & Distributors Pvt.Ltd. Reprint,2010; 361-380.
19. Kobayashi H and Brachial N.W, Dendrimer- based macromolecular MRI contrast agents. Mol. Imaging, 2003; 2(1):1-10.
20. Sonke S and Tomalia DA, Dendrimers in biomedical applications reflections on the Field.Advanced Drug Delivery Reviews, 2005; 57: 2106 – 2129.
21. Malik N, Evagorou EG, Duncan R, Dendrimer–platinate: a novel approach to cancer chemotherapy, Anticancer Drugs, 1999; 10:767–776.
22. Nanjwade BK,Kishore VS, Thakare SA,Novel Drug Delivery Systems and Regulatory Affairs. IKON BOOKS, Publishers and Distributors, New Delhi, 2011; 14:29-33.
23. Cheng Y, Man N, Xu T, Fu R, Wang X, Wang X, Wen L, Transdermal delivery of nonsteroidal anti-inflammatory drugs mediated by polyamidoamine (PAMAM) dendrimers, J. Pharm. Sci.,2007; 96: 595–602.
24. Tolia GT, Choi HH and Ahsan F, The role of dendrimers in drug delivery, Pharmaceut. Tech., 2008; 32: 88–98.
25. Vandamme T.F, Brobeck L, Poly (amidoamine) dendrimers as ophthalmic vehicles for ocular delivery of pilocarpine nitrate and tropicamide. J. Control. Release, 2005; 102(1):23–38.
26. Patelhn, and Patelpm, Dendrimer Applications – A Review. Int J Pharm Bio Sci 2013 Apr; 4(2):454 – 463.
27. Kesharwani P, Jain K, Jain N K., Dendrimer as nano carrier for drug delivery. Progress in Polymer Science, 2014; 39: 268–307.
28. Twyman LJ, Beezer AE, Esfand R, Hardy MJ, Mitchell JC, The Synthesis of Water-Soluble Dendrimers, and their application as possible drug delivery systems. Tetrahedron Lett, 1999; 40(9):1743-1746.
29. Teresa S, Barata, Teo I, Brocchini S, Zloh MM, Shaunak S, Partially Glycosylated Dendrimers Block MD-2 and Prevent TLR4-MD-2-LPS Complex Mediated Cytokine Responses. PLoS Computational Biology, 2011; 7(6):1-12.
30. Mullarkey M, Rose JR, Bristol J, Kawata T, Kimura A, Inhibition of endotoxin response by e5564, a novel TLR4-directed endotoxin antagonist. J Pharmacol Exp Ther, 2003; 304(3):1093–1102.
31. Cheng Y, Man N, Xu T, Fu R, Wang X, Wang X, Wen L, Transdermal delivery of nonsteroidal anti-inflammatory drugs mediated by polyamidoamine (PAMAM) dendrimers. J. Pharm. Sci., 2007; 96(3): 595–602.
32. Tomalia DA, Baker H, Dewald JR, Hall M, Kallos G, Martin S, Roeck J, Ryder J, Smith P, Dendrimers II: Architecture, nanostructure and supramolecular chemistry. Macromolecules, 1986; 19:2466.
33. Froehling PE, Dendrimers and dyes – a review. Dyes and pigments, 2001; 48(3):187-195.
34. Jain NK, Gupta U, Application of dendrimer-drug complexation in the enhancement of drug solubility and bioavailability. Expert Opin Drug MetabToxicol, 2008; 8(14):1035-1045.
35. Raetz CR, Whitfield C, Lipopolysaccharide endotoxins. Annu Rev Biochem, 2002; 71:635–700.
Published
How to Cite
Issue
Section
AUTHORS WHO PUBLISH WITH THIS JOURNAL AGREE TO THE FOLLOWING TERMS:
Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution-NonCommercial 4.0 Unported License. that allows others to share the work with an acknowledgment of the work's authorship and initial publication in this journal.
Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgment of its initial publication in this journal.
Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).
.